A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries
Purpose/aim of the study There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.Materials and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2443110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556985882869760 |
|---|---|
| author | Amani Alfalasi Ahmed Ameen Atlal Al Lafi Ayman El Gendi Waqas Saad Ahmed Ismail Ayman Al Naeem Srikumar Goturu Nasser Al-Ahmed Hussein Abdel Dayem Arti Nanda Amira Tawdy Lulwa Alogayell Mohamed Iraqi Nasser Abdul Hay Manar El Enezi Subash Walkhinde Marwa Kamal Muna Aldhuhoori Asem Almesfer Amira Abd Elwhab Khalid Ali Al Hawsawi Ahmad Barakat Sahar Chmayse Mohammed Hafiz Zahir Chouikrat Monica Fahmy |
| author_facet | Amani Alfalasi Ahmed Ameen Atlal Al Lafi Ayman El Gendi Waqas Saad Ahmed Ismail Ayman Al Naeem Srikumar Goturu Nasser Al-Ahmed Hussein Abdel Dayem Arti Nanda Amira Tawdy Lulwa Alogayell Mohamed Iraqi Nasser Abdul Hay Manar El Enezi Subash Walkhinde Marwa Kamal Muna Aldhuhoori Asem Almesfer Amira Abd Elwhab Khalid Ali Al Hawsawi Ahmad Barakat Sahar Chmayse Mohammed Hafiz Zahir Chouikrat Monica Fahmy |
| author_sort | Amani Alfalasi |
| collection | DOAJ |
| description | Purpose/aim of the study There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.Materials and methods This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days. Disease control, itching/pruritus, and patient satisfaction were assessed using Scoring Atopic Dermatitis (SCORAD), AD Control Tool (ADCT), and Patient Global Assessment of Treatment Effect (PGATE) scores at weeks 4, 12, and 24.Results The study included 187 participants with a mean age of 33.6 years. After 24 weeks, 75.1% of patients achieved disease control (ADCT score <7) compared to 4.3% at baseline (p < 0.001). Both ADCT and SCORAD scores significantly decreased from baseline scores (from 16.5 to 4.1 and 57.5 to 13.4, respectively, p < 0.001). Also, patient satisfaction improved significantly, with 65.3% reporting “Very Good” or “Excellent” PGATE scores in the 24th week compared to 20.3% at the baseline (p < 0.001). The limitations are the small number of included patients and the lack of long-term safety data.Conclusion In conclusion, Dupilumab therapy is effective in controlling symptoms of moderate-to-severe AD patients in the Gulf countries. Most patients achieved high disease control and satisfaction levels. |
| format | Article |
| id | doaj-art-04b4eadf03a143a8aea51ce2e4761a33 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-04b4eadf03a143a8aea51ce2e4761a332025-01-07T00:58:36ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2024.2443110A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countriesAmani Alfalasi0Ahmed Ameen1Atlal Al Lafi2Ayman El Gendi3Waqas Saad4Ahmed Ismail5Ayman Al Naeem6Srikumar Goturu7Nasser Al-Ahmed8Hussein Abdel Dayem9Arti Nanda10Amira Tawdy11Lulwa Alogayell12Mohamed Iraqi13Nasser Abdul Hay14Manar El Enezi15Subash Walkhinde16Marwa Kamal17Muna Aldhuhoori18Asem Almesfer19Amira Abd Elwhab20Khalid Ali Al Hawsawi21Ahmad Barakat22Sahar Chmayse23Mohammed Hafiz24Zahir Chouikrat25Monica Fahmy26Department of Dermatology, Dubai Health, Dubai, United Arab Emirates (UAE);Department of Dermatology, NMC Specialty Hospital, Abu Dhabi, UAEHead of Dermatology Department, As’ad Al Hamad Dermatology Center and President, Kuwait Society of Dermatologists, Kuwait City, KuwaitDepartment of Dermatology, Saudi Airlines Medical Services Center, Saudi ArabiaDermatology and Venereology, Head of Dermatology Department, Al Qassimi Hospital, Sharjah, UAEDermatology Consultant and Head of Dermatology Department at Dr Erfan, Bagedo General Hospital, Jeddah, Saudi ArabiaHead of Dermatology Department, Ibrahim Bin Hamad Obaidallah Hospital, Emirates Health Services, Ras Al Khaimah, UAEHead of Dermatology Centre at Amber Clinics, Joseph’s Polyclinic, Dubai, UAEConsultant Allergy and Clinical Immunology, Al Rashed Allergy Center, Kuwait City, KuwaitHead of Department, Mediclinic Al Noor Hospital, Abu Dhabi, UAEHead of Pediatric Dermatology Department, As’ad Al Hamad Dermatology Center, Kuwait, KuwaitHead of the Dermatology Department at Myclinic, Jeddah, Saudi ArabiaDermatology Unit, King Fahad Medical City, Riyadh, Saudi ArabiaDermatology Department, Specialized Medical Center, Riyadh, Saudi ArabiaDermatology Department, Al Mana General Hospital, Al Khobar, Saudi ArabiaHead of Dermatology Department and Consultant Dermatologist, Mubarak Al Kabeer Hospital, Jabriya, KuwaitDermatology Department, Mediclinic Welcare Hospital, Dubai, UAEDermatology Department, Medclinic Airport Road Hospital, Abu Dhabi, UAEDermatology Department, Al Qassimi Hospital, Sharjah, UAEDermatology Department, King Fahad Medical City, Riyadh, Saudi ArabiaDermatology Department, Mubarak Alkabeer Hospital, Kuwait City, KuwaitDermatology Department, King Abdulaziz Hospital, Makkah, Saudi ArabiaSanofi-Medical Manager Greater Gulf, UAESanofi-Medical Advisor Gulf, UAESanofi-Medical Advisor KSA, UAESanofi-Medical Innovation Hub Lead Greater Gulf, UAESanofi-Evidence Generation and Dissemination Manager Greater Gulf, UAEPurpose/aim of the study There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.Materials and methods This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days. Disease control, itching/pruritus, and patient satisfaction were assessed using Scoring Atopic Dermatitis (SCORAD), AD Control Tool (ADCT), and Patient Global Assessment of Treatment Effect (PGATE) scores at weeks 4, 12, and 24.Results The study included 187 participants with a mean age of 33.6 years. After 24 weeks, 75.1% of patients achieved disease control (ADCT score <7) compared to 4.3% at baseline (p < 0.001). Both ADCT and SCORAD scores significantly decreased from baseline scores (from 16.5 to 4.1 and 57.5 to 13.4, respectively, p < 0.001). Also, patient satisfaction improved significantly, with 65.3% reporting “Very Good” or “Excellent” PGATE scores in the 24th week compared to 20.3% at the baseline (p < 0.001). The limitations are the small number of included patients and the lack of long-term safety data.Conclusion In conclusion, Dupilumab therapy is effective in controlling symptoms of moderate-to-severe AD patients in the Gulf countries. Most patients achieved high disease control and satisfaction levels.https://www.tandfonline.com/doi/10.1080/09546634.2024.2443110Atopic dermatitisitchdupilumabADCTreal-world evidencegulf |
| spellingShingle | Amani Alfalasi Ahmed Ameen Atlal Al Lafi Ayman El Gendi Waqas Saad Ahmed Ismail Ayman Al Naeem Srikumar Goturu Nasser Al-Ahmed Hussein Abdel Dayem Arti Nanda Amira Tawdy Lulwa Alogayell Mohamed Iraqi Nasser Abdul Hay Manar El Enezi Subash Walkhinde Marwa Kamal Muna Aldhuhoori Asem Almesfer Amira Abd Elwhab Khalid Ali Al Hawsawi Ahmad Barakat Sahar Chmayse Mohammed Hafiz Zahir Chouikrat Monica Fahmy A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries Journal of Dermatological Treatment Atopic dermatitis itch dupilumab ADCT real-world evidence gulf |
| title | A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries |
| title_full | A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries |
| title_fullStr | A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries |
| title_full_unstemmed | A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries |
| title_short | A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries |
| title_sort | real world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy with atopic dermatitis control tool in gulf countries |
| topic | Atopic dermatitis itch dupilumab ADCT real-world evidence gulf |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2443110 |
| work_keys_str_mv | AT amanialfalasi arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT ahmedameen arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT atlalallafi arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT aymanelgendi arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT waqassaad arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT ahmedismail arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT aymanalnaeem arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT srikumargoturu arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT nasseralahmed arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT husseinabdeldayem arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT artinanda arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT amiratawdy arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT lulwaalogayell arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT mohamediraqi arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT nasserabdulhay arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT manarelenezi arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT subashwalkhinde arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT marwakamal arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT munaaldhuhoori arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT asemalmesfer arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT amiraabdelwhab arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT khalidalialhawsawi arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT ahmadbarakat arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT saharchmayse arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT mohammedhafiz arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT zahirchouikrat arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT monicafahmy arealworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT amanialfalasi realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT ahmedameen realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT atlalallafi realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT aymanelgendi realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT waqassaad realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT ahmedismail realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT aymanalnaeem realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT srikumargoturu realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT nasseralahmed realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT husseinabdeldayem realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT artinanda realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT amiratawdy realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT lulwaalogayell realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT mohamediraqi realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT nasserabdulhay realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT manarelenezi realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT subashwalkhinde realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT marwakamal realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT munaaldhuhoori realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT asemalmesfer realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT amiraabdelwhab realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT khalidalialhawsawi realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT ahmadbarakat realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT saharchmayse realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT mohammedhafiz realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT zahirchouikrat realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries AT monicafahmy realworldstudytoassessthediseasecontrolofmoderatetosevereatopicdermatitisinpatientsreceivingdupilumabtherapywithatopicdermatitiscontroltoolingulfcountries |